All articles tagged with #glp 1 therapies
Alzheimer’s research has shifted from treating symptoms to preventing cognitive decline. New blood tests can detect the disease up to ten years before symptoms appear, while early-stage trials for drugs like trontinemab aim to stop the disease before it starts. Although current treatments only modestly slow decline, experts believe acting earlier in the disease process could prevent many cases.
Recent advances in Alzheimer’s research include the FDA approval of two drugs, lecanemab and donanemab, which target amyloid plaques and may slow cognitive decline. Scientists are also exploring new targets such as tau proteins, inflammation, and GLP-1-based therapies to improve vascular health and reduce dementia risk. While many treatments remain in early-stage trials, these developments suggest a shift toward a broader and more effective treatment toolkit.
A podiatrist explains that rapid weight loss from GLP-1 drugs like Ozempic can thin the foot’s fat pads, shrink intrinsic foot muscles, and cause structural changes that make shoes no longer fit, leading to pain, blisters, and ulcers—especially for people with diabetes. Practical steps include re-measuring shoe size, adding cushioning (heel cups, metatarsal pads, cushioned insoles), choosing well-cushioned shoes, strengthening the feet and overall body, moisturizing the skin, and checking feet daily; the weight loss benefits remain, but foot care during the transition is essential.
Eli Lilly CEO David Ricks says GLP-1 drugs could be more transformative than AI, with strong weight‑loss and health benefits that could curb the roughly $1.4 trillion annual obesity‑related healthcare costs. He notes pricing moves and upcoming Medicare access (around $50 a month starting July) could broaden adoption, while Lilly’s tirzepatide program underscores how GLP‑1 therapies might reshape U.S. healthcare and chronic disease management.
The FDA proposes excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, saying there is no clinical need for outsourcing facilities to compound these drugs from bulk substances. The agency invites comments by June 29, 2026, and will consider them before a final determination, citing patient safety and the integrity of the drug-approval process.
The WHO has issued its first guidelines on GLP-1 medications for obesity, emphasizing that these drugs should be part of a comprehensive approach including lifestyle changes, and highlighting the need for increased global access and long-term care strategies. While effective, GLP-1 therapies are not a cure-all and should be used with caution, especially considering their rising popularity and social implications.
The World Health Organization has issued its first guideline on using GLP-1 medicines to treat obesity, emphasizing that these therapies can support long-term management of obesity alongside lifestyle changes, but should be part of a comprehensive approach. The guideline highlights the importance of equitable access, health system readiness, and multisectoral strategies to address the global obesity crisis, which affects over 1 billion people and causes millions of deaths annually.
Weight loss medications, such as the popular GLP-1 therapies, are proving to be effective tools for patients struggling with obesity, with some achieving significant weight loss comparable to bariatric surgery. However, these medications come with lifelong commitments and high costs, with Medicare not covering anti-obesity drugs. While these medications show promise in curbing hunger and cravings, they also come with potential side effects and are not a one-size-fits-all solution. Despite the challenges, patients like Niki Hernandez and her mother Faith Baran are finding success with these medications, highlighting the ongoing struggle and need for effective long-term solutions in managing obesity.